Methods of reduction of cisplatin nephrotoxicity.
Cisplatin, an agent widely used in the chemotherapy of a variety of human malignancies, is often dose-limited owing to its nephrotoxicity. Some of the approaches under consideration, regarding the reduction of cisplatin nephrotoxicity, include the use of hydration and osmotic diuresis, pharmacological diuretics, chelating agents or agents which otherwise react with cisplatin or reverse cisplatin-induced deoxyribonucleic acid cross-links, and antioxidants to destroy free radicals, especially superoxide radicals, produced by cisplatin. The effects of each of these and other interventions on cisplatin-induced nephrotoxicity are delineated, along with their proposed mechanisms and effects on therapeutic efficacy. The current status of development of organoplatinum analogs yielding congeners with less nephrotoxicity and greater efficacy is discussed briefly. Finally, a possible role of endogenous and/or exogenous prostaglandins in protecting against or reversing heavy metal nephrotoxicity is suggested.
D004999:Amifostine / Q000627:therapeutic use; D002945:Cisplatin / Q000633:toxicity*; D004050:Ditiocarb / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000517:prevention & control*; D008353:Mannitol / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D011339:Probenecid / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000627:therapeutic use; D013885:Thiosulfates / Q000627:therapeutic use; D013890:Thiourea / Q000627:therapeutic use
D013885:Thiosulfates; D008353:Mannitol; D005665:Furosemide; D004050:Ditiocarb; D013482:Superoxide Dismutase; D010396:Penicillamine; D013890:Thiourea; D004999:Amifostine; D011339:Probenecid; D002945:Cisplatin